These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 32152698

  • 1. Genetic susceptibility to EBV infection: insights from inborn errors of immunity.
    Tangye SG.
    Hum Genet; 2020 Jun; 139(6-7):885-901. PubMed ID: 32152698
    [Abstract] [Full Text] [Related]

  • 2. Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.
    Worth AJ, Houldcroft CJ, Booth C.
    Br J Haematol; 2016 Nov; 175(4):559-576. PubMed ID: 27748521
    [Abstract] [Full Text] [Related]

  • 3. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases.
    Latour S, Fischer A.
    Immunol Rev; 2019 Sep; 291(1):174-189. PubMed ID: 31402499
    [Abstract] [Full Text] [Related]

  • 4. Inherited Immunodeficiencies With High Predisposition to Epstein-Barr Virus-Driven Lymphoproliferative Diseases.
    Latour S, Winter S.
    Front Immunol; 2018 Sep; 9():1103. PubMed ID: 29942301
    [Abstract] [Full Text] [Related]

  • 5. Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection.
    Tangye SG, Latour S.
    Blood; 2020 Feb 27; 135(9):644-655. PubMed ID: 31942615
    [Abstract] [Full Text] [Related]

  • 6. Primary immunodeficiencies predisposed to Epstein-Barr virus-driven haematological diseases.
    Parvaneh N, Filipovich AH, Borkhardt A.
    Br J Haematol; 2013 Sep 27; 162(5):573-86. PubMed ID: 23758097
    [Abstract] [Full Text] [Related]

  • 7. The immunology of Epstein-Barr virus-induced disease.
    Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD.
    Annu Rev Immunol; 2015 Sep 27; 33():787-821. PubMed ID: 25706097
    [Abstract] [Full Text] [Related]

  • 8. When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.
    Sacco KA, Notarangelo LD, Delmonte OM.
    Clin Microbiol Infect; 2023 Apr 27; 29(4):457-462. PubMed ID: 36209991
    [Abstract] [Full Text] [Related]

  • 9. Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.
    Heslop HE.
    Hematology Am Soc Hematol Educ Program; 2005 Apr 27; ():260-6. PubMed ID: 16304390
    [Abstract] [Full Text] [Related]

  • 10. Immunity to EBV as revealed by immunedeficiencies.
    Fournier B, Latour S.
    Curr Opin Immunol; 2021 Oct 27; 72():107-115. PubMed ID: 33989894
    [Abstract] [Full Text] [Related]

  • 11. High incidence of Epstein-Barr virus (EBV)-positive Hodgkin lymphoma and Hodgkin lymphoma-like B-cell lymphoproliferations with EBV latency profile 2 in children with interleukin-2-inducible T-cell kinase deficiency.
    Bienemann K, Borkhardt A, Klapper W, Oschlies I.
    Histopathology; 2015 Nov 27; 67(5):607-16. PubMed ID: 25728094
    [Abstract] [Full Text] [Related]

  • 12. Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients.
    Okano M, Gross TG.
    Expert Rev Anti Infect Ther; 2007 Jun 27; 5(3):403-13. PubMed ID: 17547505
    [Abstract] [Full Text] [Related]

  • 13. Senile Epstein-Barr virus-associated B-cell lymphoproliferative disorders: a mini review.
    Shimoyama Y, Oyama T, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Nakamura S.
    J Clin Exp Hematop; 2006 Mar 27; 46(1):1-4. PubMed ID: 17058802
    [Abstract] [Full Text] [Related]

  • 14. Cytotoxicity in Epstein Barr virus specific immune control.
    Münz C.
    Curr Opin Virol; 2021 Feb 27; 46():1-8. PubMed ID: 32771660
    [Abstract] [Full Text] [Related]

  • 15. [EBV and immunodeficiency].
    Dieudonne Y, Martin M, Korganow AS, Boutboul D, Guffroy A.
    Rev Med Interne; 2021 Dec 27; 42(12):832-843. PubMed ID: 33867195
    [Abstract] [Full Text] [Related]

  • 16. Human B cells on their route to latent infection--early but transient expression of lytic genes of Epstein-Barr virus.
    Kalla M, Hammerschmidt W.
    Eur J Cell Biol; 2012 Jan 27; 91(1):65-9. PubMed ID: 21450364
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus: dermatologic associations and implications: part II. Associated lymphoproliferative disorders and solid tumors.
    Eminger LA, Hall LD, Hesterman KS, Heymann WR.
    J Am Acad Dermatol; 2015 Jan 27; 72(1):21-34; quiz 35-6. PubMed ID: 25497918
    [Abstract] [Full Text] [Related]

  • 18. The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.
    Martinez OM, Krams SM.
    Transplantation; 2017 Sep 27; 101(9):2009-2016. PubMed ID: 28376031
    [Abstract] [Full Text] [Related]

  • 19. Primary Immunodeficiencies Associated with EBV Disease.
    Cohen JI.
    Curr Top Microbiol Immunol; 2015 Sep 27; 390(Pt 1):241-65. PubMed ID: 26424649
    [Abstract] [Full Text] [Related]

  • 20. Systemic Epstein-Barr virus positive T-cell lymphoproliferative disease of childhood with hemophagocytic syndrome.
    Chen G, Chen L, Qin X, Huang Z, Xie X, Li G, Xu B.
    Int J Clin Exp Pathol; 2014 Sep 27; 7(10):7110-3. PubMed ID: 25400806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.